Skip to main content
. Author manuscript; available in PMC: 2014 Apr 3.
Published in final edited form as: Am J Nephrol. 2013 Apr 3;37(5):10.1159/000349930. doi: 10.1159/000349930

Table 2. Clinical information and laboratory parameters at the time of OGTT.

Metabolic syndrome p

Yes (34) No (40)
Winter season, n (&percnt);) 11 (32.4) 8 (20.0) 0.23
Vitamin D supplementation, n (%) 4 (11.8) 2 (5.0) 0.40
Calcium supplementation, n (%) 1 (2.9) 6 (15.0) 0.12
25[OH]D, ng/ml (SD) 20.5 (7.2) 24.8 (11.1) 0.049
iPTH, pg/ml (SD) 148.4 (186) 95.5 (56.2) 0.12
Serum calcium, mg/dl (SD) 9.6 (0.6) 9.6 (0.7) 0.90
Serum adiponectin, μg/ml (SD) 8.2 (4.5) 14.6 (8.0) <0.0001
Fasting glucose, mg/dl (SD) 100.7 (13.7) 91.8 (11.2) 0.004
Fasting insulin, μU/ml (SD) 29.1 (23.3) 24.6 (22.8) 0.40
HOMA-IR, (SD) 7.2 (5.8) 5.7 (5.8) 0.28
2-hours OGTT glucose, mg/dl (SD) 133.5 (45.0) 112.9 (35.1) 0.03
Glycated hemoglobin 1c, A1c (%) 5.5 (0.6) 5.4 (0.5) 0.25
Uric acid, mg/dl (SD) 7.1 (1.2) 6.2 (1.6) 0.01
Use of allopurinol, n (%) 5 (14.7) 5 (12.5) 0.78
Triglyceride, mg/dl (SD) 224.8 (94.9) 127.3 (49.6) <0.001
HDL cholesterol, mg/dl (SD) 45.4 (13.5) 57.0 (16.8) 0.002
LDL cholesterol, mg/dl (SD) 131.1 (35.0) 117.1 (44.5) 0.13
Use of statins, n (%) 5 (14.7) 5 (12.5) 0.78
Systolic BP, mmHg (SD) 132.2 (17.5) 134.6 (16.4) 0.55
Diastolic BP, mmHg (SD) 76.0 (9.2) 77.3 (9.2) 0.54
Pulse pressure, mmHg (SD) 56.2 (16.3) 57.3 (15.8) 0.78
Hypertension drugs, n (SD) 1.8 (0.9) 1.6 (0.8) 0.29